Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study
FGFR3 status did not significantly impact response to PBC in first-line treatment or ICIs. These findings underscore that the presence of an FGFR3 alteration does not guide the choice of platinum-based treatment, and the need for prospective biomarker-driven trials to identify best treatment sequences in advanced UC.
Authors
- Aude Fléchon (ORCID: https://orcid.org/0000-0002-0129-6101)
- Fabien Moinard‐Butot (ORCID: https://orcid.org/0000-0002-5630-5220)
- Diego Teyssonneau (ORCID: https://orcid.org/0000-0002-9687-3759)
- Denis Maillet (ORCID: https://orcid.org/0000-0001-6883-2696)
- Sophie Tartas
- Constance Thibault (ORCID: https://orcid.org/0000-0002-9082-1341)
- Thibaut Reverdy
- Nadine Houédé (ORCID: https://orcid.org/0000-0002-8852-5754)
- Guilhem Roubaud
- Hugo Berthou
- Floriane Izarn (ORCID: https://orcid.org/0000-0002-4116-8243)
- Benoît Allignet (ORCID: https://orcid.org/0000-0001-7275-0773)
- Philippe Barthélémy (ORCID: https://orcid.org/0009-0006-3868-186X)
- Nyere Gibson
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université de Montpellier (FR)
- Université Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Centre Léon Bérard (FR)
- Hôpital Européen (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
- Institut Bergonié (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Université de Nîmes (FR)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1016/j.clgc.2025.102465
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00